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ABSTRACT 
BACKGROUND AND AIMS 
Primary Sclerosing Cholangitis (PSC) is an inflammatory, cholestatic and progressively fibrotic liver 
disease devoid of effective medical intervention. NGM282, an engineered, non-tumorigenic FGF19 
analogue, potently regulates CYP7A1-mediated bile acid homeostasis.  We assessed the activity and 
safety of NGM282 in patients with PSC.  
METHODS 
In this double-blind, placebo-controlled phase 2 trial, patients who had PSC confirmed by 
cholangiography or biopsy and an elevated alkaline phosphatase (ALP) >1.5xULN were randomly 
assigned 1:1:1 to receive NGM282 1 mg, 3 mg or placebo once daily for 12 weeks. The primary 
outcome was the change in ALP from baseline to week 12. Secondary and exploratory outcomes 
included changes in serum biomarkers of bile acid metabolism and fibrosis. Efficacy analysis was by 
intention-to-treat. 
RESULTS 
62 patients were randomized to receive NGM282 1 mg (n=21), NGM282 3 mg (n=21) or placebo 
(n=20). At 12 weeks, there were no significant differences in the mean change from baseline in ALP 
between the NGM282 and placebo groups, and therefore, the primary endpoint was not met. 
However, NGM282 significantly reduced levels of 7alpha-hydroxy-4-cholesten-3-one (a marker of 
hepatic CYP7A1 activity, LS mean differences −6.2 ng/mL [95% CI −10.7 to −1.7; P=0.008] and −9.4 
ng/mL [−14.0 to −4.9; P<0.001] in the NGM282 1 mg and 3 mg groups, respectively, compared with 
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placebo) and bile acids. Importantly, fibrosis biomarkers that predict transplant-free survival, including 
Enhanced Liver Fibrosis score and Pro-C3, were significantly improved following NGM282 treatment. 
Most adverse events were mild to moderate in severity, with gastrointestinal symptoms more frequent 
in the NGM282 treatment groups.   
CONCLUSIONS 
In patients with PSC, NGM282 potently inhibited bile acid synthesis and decreased fibrosis markers, 
without significantly affecting ALP levels. 
  
(Abstract Word Count: 274) 
 
LAY SUMMARY 
We present for the first time, the clinical and laboratory effects of a first-in-class, engineered analogue 
of the endocrine hormone FGF19 in patients with PSC.  By incorporating non-invasive markers of 
fibrosis, beyond standard liver injury markers, we show that NGM282 impacted on fibrosis turnover 
and hepatic inflammation without changing alkaline phosphatase. Our findings demonstrate the 
complexities of using highly potent rational agents in PSC, and furthermore challenge the dogma about 
what the appropriate endpoints should be for trials in PSC.   
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INTRODUCTION 
 
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by strictures of the biliary 
tree and presently devoid of medical treatment[1]. Of the histopathological hallmarks of PSC, 
periductal inflammation and “onion skin”-like fibrosis, referring to concentric layers of collagen fibers 
circumferential to the cholangiocyte lining of the bile ducts, characterize a progressive fibrosing 
cholangiopathy[2]. Patients frequently present with concurrent inflammatory bowel disease (IBD), and 
are at increased risk of developing hepatobiliary and colon cancers. More than 50% of patients need 
liver transplantation within 10-15 years of symptom development[1]. Biochemically, PSC is 
characterized by elevated serum liver tests, and alkaline phosphatase (ALP) levels associate with future 
risk of adverse events. 
 
There remains no single specific cause of PSC, and etio-pathogenesis is believed to encompass genetic, 
chemical, environmental (including microbiome factors) and immunologic pathways to selective biliary 
epithelial damage[1]. A prevalent “toxic bile” hypothesis posits that early pathogenesis of disease 
results from injury on the integrity of biliary epithelium, leading to retention of bile acids and 
intrahepatic inflammation and fibrosis. Treatments that ameliorate bile acid toxicity, or that increase 
the efflux of bile acids, may slow the progression of PSC[3]. UDCA, a hydrophilic bile acid, has been 
widely prescribed in PSC but without definitive evidence of its clinical benefit, seemingly having 
choleretic properties but not anti-fibrotic efficacy.  
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Fibroblast growth factor 19 (FGF19), an endocrine gastrointestinal hormone, controls bile acid 
metabolism via actions on CYP7A1, the first and rate-limiting enzyme in the classic pathway of bile acid 
synthesis[4, 5]. Circulating FGF19 concentration is increased in patients with PSC, further suggesting 
that FGF19 may represent an adaptive mechanism in PSC-related progressive liver diseases[6, 7]. 
However, the therapeutic potential of FGF19 has been hindered by its hepatocarcinogenicity[8]. 
NGM282 (also known as M70), a non-tumorigenic analogue of FGF19, was designed to retain CYP7A1 
suppression to reduce bile acid-associated biliary injury[9]. In NGM282, a five-amino acid deletion 
(P24-S28) coupled with the substitution of three amino acids at critical positions (A30S, G31S, H33L) 
within the amino terminus, enable biased FGFR4 signaling so that NGM282 does not activate signal 
transducer and activator of transcription 3, a signaling pathway essential for FGF19-mediated 
hepatocarcinogenesis[10]. In animal models of PSC, treatment with NGM282 resulted in a rapid and 
robust reduction in ALP, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
concentrations, as well as a clear improvement in histological features associated with PSC, including 
hepatic inflammation and “onion skin”-like periductal fibrosis[11]. NGM282 was safe and well 
tolerated in healthy volunteers and in patients with non-alcoholic steatohepatitis (NASH)[12, 13]. 
 
We therefore conducted a phase 2, multicenter, international, randomized, double-blind, placebo-
controlled trial to evaluate the efficacy and safety of NGM282 versus placebo in adult patients with 
PSC. 
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PATIENTS AND METHODS 
OVERSIGHT 
The trial protocol was approved by the ethics committees and institutional review boards at each 
participating site prior to study initiation. The study was conducted according to the provisions of the 
Declaration of Helsinki and in compliance with International Conference on Harmonization Good 
Clinical Practice guidelines. All patients provided written informed consent before participation in the 
trial. An independent data and safety monitoring board reviewed safety data. This study was designed 
by expert clinicians who had experience in treating PSC in conjunction with representatives of the 
sponsor. Data were collected by investigators, and managed, validated and analyzed by Pharmaceutical 
Product Development (Morrisville, NC). The authors had access to the data after unblinding, 
participated in data analysis and interpretation, and vouch for the fidelity of the study to the protocol 
and the accuracy of the data. All authors participated in the manuscript development and provided 
final approval to submit. 
 
PATIENTS 
This multicenter, international trial included male and female patients, 18 to 75 years of age, who met 
the diagnostic criteria for PSC according to the EASL and AASLD guidelines[14, 15]. Patients were 
eligible if they met the following inclusion criteria: 18 to 75 years of age at the time of screening; 
confirmed diagnosis of PSC (based on any 2 of the 3 criteria: abnormal cholangiography consistent with 
PSC as measured by magnetic resonance cholangiopancreatography, endoscopic retrograde 
cholangiopancreatography or percutaneous transhepatic cholangiography; liver biopsy consistent with 
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PSC; historical evidence of elevated ALP); ALP >1.5xULN; ALT and AST <5xULN; bilirubin ≤2.5 mg/dL. 
Patients taking UDCA were allowed to enroll if on stable dose (<27 mg/kg/day) within 2 months of 
screening. Patients were also allowed to enroll if they had dominant strictures with no evidence of 
clinical concern, IBD with no episode of flare, autoimmune hepatitis on stable immunosuppressive 
regimen with no hepatic flare, compensated cirrhosis or pre-sinusoidal esophageal varices with no 
history of bleeding and no other evidence of hepatic decompensation. Exclusion criteria included 
clinically significant acute or chronic liver disease of an etiology other than PSC; evidence of secondary 
or immunoglobulin G4-related sclerosing cholangitis per EASL guidelines [14]; placement of a bile duct 
stent or percutaneous bile duct drain within 3 months of screening; decompensated cirrhosis; and liver 
transplantation. A complete list of inclusion and exclusion criteria is provided in Supplementary Table 
1.   
 
RANDOMIZATION AND MASKING 
Patients were randomly assigned by means of an Interactive Web Response System in a 1:1:1 ratio to 
once daily subcutaneous NGM282 (NGM Biopharmaceuticals, South San Francisco) 1 mg, NGM282 3 
mg or placebo. Randomization was stratified according to UDCA use (yes or no) to ensure an even 
distribution across the treatment arms. The determination of UDCA status was based on medical 
history and concomitant medication at randomization.  NGM282 and placebo were provided as 
identical pre-filled syringes in identical containers labelled with unique code numbers, in keeping with 
Good Manufacturing Practice for medicinal products guidelines. A master control list of the pack 
identification numbers and treatment was accessible by the statistician who prepared the 
randomization schedule. The list was also provided to the contract research organization of the 
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emergency un-blinding service. Investigators, staff, patients, sponsor, and medical monitor remained 
blinded throughout the study period.  
 
OUTCOMES 
The primary outcome measure was the change in ALP from baseline to end of treatment (EOT) at week 
12. Secondary and exploratory outcomes included changes in 7alpha-hydroxy-4-cholesten-3-one (C4, a 
serum marker of hepatic CYP7A1 activity indicative of target engagement), bile acids, ALT, AST, and 
markers of fibrosis, such as total enhanced liver fibrosis (ELF) score (including the N-terminal pro-
peptide of type III collagen [PIIINP], the tissue inhibitor of metalloproteinase 1 [TIMP-1] and hyaluronic 
acid; measured on ADVIA Centaur® CP Immunoassay System from Siemens) and Pro-C3 (which 
measures a neo-epitope of type III collagen during collagen formation and reflects fibrogenic 
activity[16]; Nordic Bioscience). AEs were assessed using the Common Terminology Criteria for Adverse 
Events v4.03. A complete list of outcome measures is provided in Supplementary Table 2.   
 
PROCEDURES 
The trial was conducted at 27 sites in Europe and US and was designed to have a screening period of 4 
weeks, a treatment period of 12 weeks and a follow-up period of 4 weeks. During the screening period, 
patients underwent MRCP for baseline assessment. Patients with concomitant IBD also underwent a 
colonoscopy procedure if historical reports were obtained 12 months or more prior to randomization. 
On day 1, study drug self-administration instructions and training were provided to patients, and a 
weekly study drug kit was dispensed. The first dose of study drug and doses at weeks 1, 2, 4, 8 and 12 
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were self-administered in the clinic; all other doses were administered at home. Patients were 
instructed to inject the study drug at the same time every morning.  
 
Laboratory and Pro-C3 were assessed at day 1, week 1, 2, 4, 8, 12 and 16 (follow-up). Levels of C4, bile 
acids, lipids and ELF scores were measured on day 1 and week 12 (EOT). Adverse events (AEs) and 
concomitant medications were evaluated at each study visit. The schedule for the study visits and data 
collection is summarized in the Supplementary Table 3.   
 
STATISTICAL ANALYSIS 
Analyses were conducted on the basis of the intention-to-treat principle and involved all patients who 
were randomized to receive NGM282 or placebo. All tests of effects were conducted at a two-sided 
alpha level of 0.05. A minimal sample size of 60 patients was selected for the pre-study power 
calculation. Allowing for a 20% dropout rate, sample size calculations were based on a minimum of 16 
completing patients per group.  
 
The mean change from baseline at week 12 in ALP (primary outcome) was compared vs placebo using 
the Wilcoxon Rank Sum test. Continuous outcomes measured repeatedly over weeks were analyzed 
with the use of a mixed-effect model repeated measures (MMRM) analysis of covariance (ANCOVA), 
with treatment group, visit, treatment group by visit interaction, UDCA use, treatment group by UDCA 
use interaction as classification variables and baseline value as covariate.  For outcomes assessed only 
at baseline and at week 12, changes were examined using an ANCOVA model with treatment group, 
visit, treatment group by visit interaction, UDCA use, treatment group by UDCA use interaction as 
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classification variables and baseline value as covariate. The overall type 1 error was controlled using 
the step-down Dunnett multiple testing procedure. Missing data were imputed using the last post-
baseline observation carried forward methodology. SAS version 9∙4 (SAS Institute, Cary, NC) was used 
to conduct the analyses. Safety and tolerability analyses were conducted in all randomized patients 
who received at least one dose, full or partial, of study drug and had at least one post-dose safety 
evaluation. All safety endpoints were analyzed descriptively. The trial was registered with 
ClinicalTrials.gov (NCT02704364).  
 
RESULTS 
Population 
Between February 25, 2016 and February 1, 2017, 95 patients underwent screening, and 62 eligible 
patients were randomized to receive NGM282 1 mg (n=21), NGM282 3 mg (n=21) or placebo (n=20) 
(Fig. 1). Baseline demographics and disease characteristics of the three dosing groups were similar 
(Table 1 and Supplementary Table 4). A total of 58 patients (95% of the patients in the NGM282 1 mg 
group, 90% of those in the NGM282 3 mg group and 95% of those in the placebo group) completed the 
12-week treatment; 4 patients (1 in the NGM282 1 mg group, 2 in the NGM282 3 mg group and 1 in 
the placebo group) withdrew from the trial before end of treatment.   
 
Primary Outcome 
 At 12 weeks, there was no significant difference in ALP with NGM282 1 mg (least squares [LS] mean 
difference, −14.0 U/L; 95% CI, −68.0 to 28.0; P=0.43) and NGM282 3 mg (13.0 U/L, −41.0 to 71.0; 
P=0.65) compared with placebo (Fig. 2A and Table 2). MMRM analyses showed significant decreases in 
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ALP by the NGM282 1 mg group at week 1, 2 and 4 compared to baseline; however, the effects were 
not maintained at week 12 (Supplementary Fig. 1). Pre-specified subgroup analyses showed a similar 
pattern of response in ALP irrespective of concomitant UDCA use. Similar changes in GGT were also 
observed (Supplementary Fig. 2).  
 
Secondary Outcomes 
Significant reductions in C4 were observed in patients who received NGM282 (Fig. 2B and Table 2). At 
12 weeks, the LS mean differences in C4 were −6.2 ng/mL (95% CI −10.7 to −1.7; P=0.008) in the 
NGM282 1 mg group and −9.4 ng/mL (95% CI −14.0 to −4.9; P<0.001) in the NGM282 3 mg group 
compared with placebo (Table 2). Furthermore, treatment with NGM282 resulted in decreases in 
circulating bile acids, and secondary bile acids in particular (DCA, GDCA, TDCA, GLCA, TLCA), compared 
with placebo-treated patients (Fig. 2C and Table 3). Despite significant inhibition of the classic pathway 
of de novo bile acid synthesis as evidenced by C4 reduction, no significant changes in serum vitamin D 
levels, an indicator of fat-soluble vitamin absorption, were observed in NGM282-treated subjects 
(Supplementary Table 5).  
 
Significant decreases in ALT and AST from baseline were in the NGM282 3 mg group during treatment 
(Figs. 2D-E). The LS mean changes in ALT levels from baseline to week 12 were 8.5 U/L (P=0.41) and 
−45.1 U/L (P<0.001) for NGM282 1 mg and 3 mg, respectively, versus −12.1 U/L (P=0.25) for placebo. 
The LS mean changes in AST levels from baseline to week 12 were −0.2 U/L (P=0.97) and −30.9 U/L 
(P<0.001) for NGM282 1 mg and 3 mg, respectively, versus −13.3 U/L (P=0.07) for placebo. Pre-
specified subgroup analyses showed similar reductions in transaminases by NGM282 treatment in 
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patients on concomitant UDCA to those not on UDCA (Supplementary Figs. 3-4). Post hoc analyses 
revealed that the trend of improvement in liver enzymes was also observed in patients with 
suppressed C4 levels at baseline, a population previously linked to worse outcomes in PSC[7], and in 
patients with large duct disease or dominant strictures (Supplementary Figs. 5-7). 
 
No significant placebo-adjusted changes from baseline to week 12 were observed for the NGM282 
groups in levels of triglycerides, total cholesterol, HDL cholesterol or LDL cholesterol (Table 2 and 
Supplementary Fig. 8). Changes from baseline to week 12 in additional parameters are summarized in 
Table 2 and Supplementary Table 6. 
 
Serum Fibrosis Biomarkers 
Levels of ELF and Pro-C3, non-invasive fibrosis biomarkers that predict transplant-free survival in 
patients with PSC[17-19], were measured at baseline and after 12 weeks of NGM282 treatment. Serum 
ELF test showed a reduction in fibrosis in patients receiving NGM282 compared with placebo (Fig. 3A 
and Table 2). The LS mean changes in ELF from baseline to week 12 were −0.29 (P=0.028) and −0.37 
(P=0.009) for NGM282 1 mg and 3 mg, respectively, versus 0.07 (P=0.56) for placebo. Improvements in 
the individual components of ELF (PIIINP, TIMP-1 and hyaluronic acid) were also observed in patients 
treated with NGM282 (Supplementary Fig. 9). Post hoc subgroup analysis revealed that patients with a 
higher risk of disease progression (ELF >9.8 at baseline[17, 18]) had a greater reduction in ELF than did 
patients with a lower disease risk, with LS mean changes of −0.52 (P<0.001) and −0.58 (P=0.007) for 
NGM282 1 mg and 3 mg, respectively, versus −0.01 (P=0.97) for placebo (Fig. 3A). 
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Pro-C3 measures a neo-epitope of type III collagen during collagen formation and directly reflects 
fibrogenic activity[16]. Reductions in Pro-C3 levels were greater for both NGM282 1 mg and 3 mg 
groups compared with the placebo group at all time points during treatment (Fig. 3B-C). At week 12, 
significant reductions in Pro-C3 were observed in the NGM282 1 mg group (LS mean difference, −9.5; 
95% CI −17.1 to −2.0; P=0.01) and 3 mg group (−13.3; −21.0 to −5.6; P=0.001) compared with the 
placebo (Table 2). Improvements in Pro-C3 were most pronounced in patients with advanced 
fibrogenesis (Pro-C3 >20 ng/mL) at baseline (Supplementary Fig. 10). 
 
Safety 
17/21 patients (81%) in the NGM282 1 mg group, 20/21 patients (95%) in the NGM282 3 mg group and 
18/20 patients (90%) in the placebo group had adverse events, most of which were grade 1 and grade 
2, during the study period (Table 4). The most commonly reported adverse events due to any cause 
were injection site reaction and diarrhea. Injection site reaction occurred more frequently in the 
NGM282 3 mg group, but appeared to be tolerated over time, as measured by the local injection site 
symptom assessment tool (Supplementary Fig. 11). Diarrhea was reported in a higher percentage of 
patients in the NGM282 groups than placebo, none higher than grade 2 in severity. Assessment of 
gastrointestinal symptoms by Mayo Partial IBD score revealed that NGM282 treatment increased stool 
frequency, but not rectal bleeding (Supplementary Fig. 12).  A total of 3 serious adverse events were 
reported during the trial. One patient from the NGM282 1 mg group had an elevation in bilirubin due 
to PSC progression and one patient from the NGM282 3 mg group had an intervertebral discitis; 
neither was considered related to treatment by site investigators.  One patient with concomitant 
ulcerative colitis in the NGM282 3 mg group had a bowel obstruction during the follow-up period after 
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EOT, which resolved in three days. This event was considered by the investigator to be possibly related 
to the study drug. No adverse events at or above grade 4 were noted. No deaths occurred during the 
course of the study. 
 
None of the patients tested positive for antidrug antibodies (ADA) at baseline. ADA occurred after 
baseline during the study period in 5 of 62 patients, all from the NGM282 3 mg group. Neutralizing 
antibodies to FGF19 were not detected in any of these patients.  There was no evidence of clinical 
safety events associated with a positive antidrug antibody test.   
 
DISCUSSION 
 
PSC is a chronic inflammatory, fibrosing and cholestatic liver disease, associated with poor outcomes 
for patients, in which the need for novel therapies is acute[20]. In our randomized, placebo-controlled, 
phase 2 trial of NGM282, drug administration did not meet the pre-specified primary endpoint of 
reductions in the serum marker of cholestasis, ALP, after 12 weeks of treatment. However, NGM282, a 
first-in-class FGF19 analogue, demonstrated potent target engagement, as evidenced by significant 
reductions in C4 and bile acids. The resulting reduction in levels of transaminases and fibrosis 
biomarkers (ELF and Pro-C3) nevertheless highlights the compartmentalized potential efficacy of this 
new treatment. In keeping with reported efficacy of NGM282 at a similar stage of drug development 
for non-alcoholic steatohepatitis[13], our trial data for the first time in PSC demonstrated a significant 
potential anti-fibrotic activity of a therapeutic agent using a novel biomarker (Pro-C3) in participants.  
  
18 
 
NGM282 was generally well tolerated at both doses, with most treatment-related AEs being mild in 
severity. 
  
The slow rate of disease progression, together with heterogeneous pathogenic mechanisms, the lack of 
defined surrogates of treatment efficacy and the impracticality of frequent liver biopsies (as opposed 
to blood sampling), have limited the development of therapeutics for PSC. At present, there are no 
established surrogate endpoints for regulatory approval in PSC. Several surrogate endpoints, including 
ALP, were recommended by an international PSC study group[21, 22]. The observation that ALP 
reduction after UDCA treatment can predict outcomes (liver transplantation and death) in primary 
biliary cholangitis (PBC) has inspired studies to assess the association between ALP reduction and 
clinical outcome after UDCA treatment in PSC. However, unlike in PBC, ALP has a more unpredictable 
fluctuating nature in PSC, which may limit the value of single measurements at any point in time for 
patient follow-up or clinical trials[2]. Cholangitis, biliary calculi or dominant strictures can cause 
transient elevations in ALP, generating difficulty in assessing disease stage and prognosis. Multiple 
trials of UDCA (13-23 mg/kg) suggested improvements in ALP but not hard endpoints such as death or 
liver transplantation[23-25]. A landmark, long-term, randomised, double-blind, placebo-controlled 
study of high-dose UDCA (28-30 mg/kg) in 150 PSC patients was terminated after 6 years due to 
worsened outcome (difference in the total number of all endpoints reached: development of cirrhosis, 
esophageal varices and cholangiocarcinoma, listing for liver transplant, and death) despite a significant 
reduction in ALP[26-29]. The relevance of ALP for treatment response in PSC is unclear at present. 
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Diagnosis of PSC depends on identification of fibrotic strictures of the intrahepatic or extrahepatic 
biliary systems, by cholangiography or biopsy[20]. The pathognomonic lesion in PSC is an “onion skin” 
scar, referring to concentric layer of fibrosis circumferential to the cholangiocyte lining of the bile 
ducts. Despite the association between liver fibrosis stage and transplant-free survival[30], liver biopsy 
was not routinely performed due to its invasive nature and inherent sampling variability in PSC. In 
contrast to previous trials, we evaluated the fibrosis biomarkers in addition to the widely-used primary 
endpoint ALP. ELF score, a composite panel of three components of fibrogenesis and matrix 
remodeling, has been demonstrated to be a strong predictor of transplant-free survival in patients with 
PSC[17, 18]. In particular, a change in ELF score of −0.19 from baseline to week 12 has been shown to 
predict survival free of PSC-related clinical events, such as ascites, encephalopathy, variceal 
hemorrhage, cholangiocarcinomas, jaundice, liver transplant or death[31]. The administered doses of 
NGM282 reduced ELF (−0.29 and −0.37 from baseline to week 12 for 1 mg and 3 mg, respectively), 
with the most pronounced improvement in patients who had an advanced stage of disease (−0.52 and 
−0.58 from baseline to week 12 for 1 mg and 3 mg, respectively, in patients with baseline ELF >9.8). 
Serum levels of Pro-C3 reflect fibrogenesis directly by detecting a neo-epitope of collagen III[16]. Pro-
C3 has recently been demonstrated to be an independent predictor of transplant-free survival in PSC, 
with an odds ratio of 13.8[19]. NGM282 treatment produced rapid, robust and sustained effect in 
lowering Pro-C3. The anti-fibrotic activity of NGM282 in this trial supports the notion that NGM282 
may eliminate toxic effects due to bile acid accumulation in the liver at a stage before the deposition of 
fibrillary proteins, and is consistent with results from animal models[11] and clinical studies in non-
alcoholic steatohepatitis[13]. Overall, the significant reduction in the levels of fibrotic and 
inflammation markers that are correlated with disease activity supports a long-held hypothesis that 
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dysregulated bile acids are a key driver of intrahepatic inflammation and fibrosis, rather than only the 
bystander of an autoimmune response. This, in turn, supports the view that a therapy targeting bile 
acid metabolism could deliver clinical benefit without having an early biochemical response in ALP.  
 
Both doses of NGM282 that were administered in this trial were associated with a high level of target 
engagement, sufficient to reduce C4 by 61-87%. It is possible that the magnitude of reduction in C4 
was simply insufficient to create a measurable effect in change from baseline in ALP, especially when 
baseline C4 levels are already suppressed by elevated FGF19 in PSC patients[3, 7], contrasting 
observations in animal models[11]. We did note a reduction in ALP within 1 week of treatment 
initiation with NGM282 1 mg, which was sustained through week 4, but diminished in magnitude at 
week 12. These findings suggest that the effects of NGM282 on ALP might be transient and reversed by 
adaptive mechanisms to re-establish a new equilibrium. In contrast, the decrease in transaminases is 
sustained and enduring in patients on NGM282 3 mg, thus the protective effect of NGM282 may be 
more parenchymal-focused rather than biliary.  
 
NGM282 was generally well tolerated in the study population. Injection site reactions occurred more 
frequently in the NGM282 3 mg group, but appeared to be tolerated over time. Gastrointestinal 
symptoms were transient and mild to moderate in severity, as observed with NGM282 treatment in 
patients with NASH[13]. Although elevation of LDL cholesterol due to inhibition of its conversion to bile 
acid was noted in previous trial of NGM282 in patients with NASH[13], we observed no significant 
change in LDL cholesterol in PSC patients. Patients with PSC frequently develop disabling pruritus and 
fatigue. NGM282 did not worsen pruritus or fatigue.  
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As a master regulator of bile acid metabolism in human physiology and health, the Farnesoid X 
receptor (FXR)-FGF19 axis is increasingly recognized as an area of great potential for the treatment of 
chronic liver disease. A significant component of FXR-mediated biological activity is attributed to the 
induction of endogenous FGF19, a bona fide FXR target gene in the gut[4]. Synthetic activators of FXR 
have been recently approved or are currently in clinical development in PBC, PSC and NASH[32-34]. We 
have recently shown that administration of NGM282 for 28 days resulted in significant improvements 
in ALP and transaminase levels compared with placebo in patients with PBC who had inadequate 
response to ursodiol. In contrast with results presented in this report, ALP was significantly reduced 
with NGM282 treatment (LS mean differences of –54 IU/L (P=0.0149) and –69 U/L (P=0.0030) for 0.3 
mg and 3 mg, respectively, versus placebo)[35]. Whereas ALP is considered “reasonably likely” to 
predict clinical outcome by the Food and Drug Administration for accelerated approval under Subpart 
H/E for PBC [36], ALP-lowering alone is not regarded as the primary efficacy outcome for clinical trials 
in PSC. Nevertheless, significant decreases in the levels of transaminases (ALT and AST) were observed 
in patients treated with NGM282 across PSC, PBC, and NASH populations[13, 35], indicating robust 
activity of NGM282 against liver injury.   
 
Our trial had several strengths. These include the enrollment of a broader patient population that is 
more reflective of real world experience. For example, patients with dominant strictures have 
significantly worse survival than do those without dominant strictures[37]; 16% of the patients in this 
study have dominant strictures compared with 0% of the patients in recent PSC trials (OCA, norUDCA, 
simtuzumab)[33, 38, 39]. Patients with small duct disease, features of autoimmune hepatitis, and 
compensated cirrhosis were included in our trial but were excluded from the other studies. 
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Importantly, we included fibrosis biomarkers that predict clinical outcome in PSC (ELF) and are novel in 
monitoring fibrogenesis (Pro-C3).   
 
Limitations of this study included a relatively short treatment period and small overall number of 
subjects. The non-invasive fibrosis biomarkers (Pro-C3 and ELF) used in this study are only of 
prognostic value[17, 19, 40], and have not yet been shown to change with disease course. Further 
studies are therefore needed to examine whether longitudinal change in these markers correlates with 
disease course, and their potential as surrogate endpoints. Whilst accepting that small duct PSC is an 
area of controversy, we elected to include such patients to ensure that the study, performed in expert 
centres with experienced Hepatologists, recruited patients for evaluation reflecting the spectrum of 
clinical PSC looked after in the community. Additional limitations include a lack of MRCP at the end of 
the treatment, although all patients had an MRCP exam during screening. As cholangiographic changes 
define the diagnosis of PSC, evaluation of therapeutics should also focus on the imaging of bile duct 
changes, given the recent study showing that MRCP score correlates with clinical outcome (variceal 
bleeding, decompensation, transplant, death) in patients with PSC[41]. Additionally, participants did 
not undergo liver biopsy at the end of the trial, therefore, it is uncertain whether NGM282-mediated 
anti-fibrotic effects can be seen at the histological level.  
 
The current trial confirms the clinical relevance of the FGF19 pathway in PSC patients and the concept 
that it could be harnessed therapeutically to change the course of the disease. Longer trials with a 
larger number of patients are however needed to better understand the effects of NGM282 therapy in 
PSC. Given that liver biopsies are not routinely conducted to assess disease progression in patients 
  
23 
 
with PSC, future trials should examine longitudinal change in transient elastography and MRCP, and 
correlate with serum markers of fibrosis turnover and hepatic inflammation. These studies will have 
important implications as they may demonstrate the complexities of testing therapeutic agents in PSC, 
and challenge the dogma about what the appropriate endpoints should be for trials in PSC. 
 
CONCLUSIONS 
In conclusion, in patients with PSC, NGM282 demonstrated significant and robust activities on bile acid 
metabolism and anti-fibrotic effects, without reducing ALP. Further trials with NGM282 in patients with 
PSC should focus on longer term administration and an array of biochemical and imaging end-points 
that reflect closer the underlying pro-fibrotic nature of PSC.  
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TABLES 
 
Table 1. Baseline Patient Demographics and Characteristics 
  Placebo (n=20) NGM282 1 mg (n=21) NGM282 3 mg (n=21) 
Mean age, years 43.4±12.4  46.0±15.9 40.2±13.0 
   Male, n (%) 12 (60)  14 (67) 12 (57) 
   Female, n (%) 8 (40)  7 (33) 9 (43) 
Duration of PSC, years 8.1±7.2  7.3±6.1 7.8±7.6 
Race, n (%) 
Asian 0 1 (5) 0 
Black 4 (20)  1 ( 5) 2 ( 10) 
White 16 (80)  18 (86) 18 (86) 
Other 0 1 ( 5) 1 ( 5) 
Ethnic origin, n (%) 
Hispanic/Latino 0 1 (5) 0 
UDCA status, n (%) 
Concomitant UDCA 13 (65) 13 (62) 13 (62) 
No concomitant UDCA 7 (35)  8 (38) 8 (38) 
Cholangiography by MRCP or ERCP, n (%) 
Large duct PSC 13 (65)  10 (48) 14 (67) 
Dominant stricture 5 (25)  2 ( 10) 3 (14) 
Bile acid-related 
C4 (ng/mL)  10.5±11.2 12.9±12.8 16.9±18.2 
        C4 ≤2 ng/mL 5 (25) 4 (19) 4 (19) 
Endogenous bile acids (µmol/L)  30.2±33.0 39.1±42.4 20.1±32.0 
Endogenous FGF19 (pg/mL) 433.3±339.1 339.7±279.5 305.8±241.1 
Serum liver tests 
Alkaline phosphatase (U/L) 355.5±137.9 383.2±181.4 353.7±194.0 
Alanine aminotransferase (U/L) 90.5±51.8  116.7±70.2 96.1±67.3 
Aspartate aminotransferase (U/L) 71.1±36.9  92.6±59.7 70.3±46.4 
Total bilirubin (µmol/L) 12.1±6.0  17.9±8.4 10.7±4.3 
Fibrosis biomarkers  
Pro-C3 (ng/mL)   26.1±16.4 26.7±17.9 24.2±16.7 
        Pro-C3 ≥20 ng/mL 12 (60) 10 (48) 10 (48) 
ELF score 10.0±1.4 10.2±1.2 9.5±1.1 
Hyaluronic acid (µg/L) 160.8±261.6 203.8±488.7 60.1±60.2 
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PIIINP (µg/L) 14.2±8.3 13.9±6.3 12.6±4.2 
TIMP-1 (µg/L) 338.6±113.6 310.4±74.6 338.4±94.1 
        ELF >9.8 9 (45) 12 (57) 5 (24) 
Shown are mean±SD or n(%). BMI, body mass index; C4, 7alpha-hydroxy-4-cholesten-3-one; ELF, Enhanced Liver Fibrosis; HDL, high-
density lipoprotein; INR, international normalized ratio; LDL, low-density lipoprotein; PIIINP, N-terminal propeptide of type III collagen; 
Pro-C3, neoepitope-specific N-terminal propeptide of type III collagen; SD, standard deviation; TIMP-1, tissue inhibitor of 
metalloproteinase 1; UDCA, ursodeoxycholic acid 
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Table 2. Key Outcomes at Week 12 
 
Mean Change From Baseline to Week 
12 (SD) 
LS Mean Difference (95% CI) 
(NGM282 vs. Placebo) 
 
Placebo 
(n=20) 
NGM282 
1mg (n=21) 
NGM282 
3mg (n=21) 
NGM282 1 mg p NGM282 3 mg p 
ALP 
Overall ALP (U/L) −0.6 
(79.5)  
25.6 
(100.3) 
−9.8 (101.3) −14.0 (−68.0, 28.0)  0.43 
13.0 (−41.0, 71.0) 
 
0.65 
Concomitant UDCA −10.2 
(73.5)  
27.1 
(122.8) 
6.3 (81.1) 11.0 (−44.0, 133.0) 0.78 7.0 (−33.0, 60.0) 0.79 
No concomitant 
UDCA 
17.1 
(93.0)  
23.1 (54.0) 
−34.0 
(128.1) 
−21.0  (−119.0, 
133.0) 
0.68 
59.0 (−157.0, 
225.0) 
0.22 
7alpha-hydroxy-4-cholesten-3-one (C4) 
C4 (ng/mL) 0.5 (11.7) −7.9 (13.3) −14.6 (17.6) −6.2 (−10.7, −1.7) 0.008 −9.4 (−14.0, −4.9) <0.001 
Liver function test 
ALT (U/L) −4.5 
(31.6) 
−2.8 (62.8) −42.7 (74.5) 20.6 (−8.8, 50.0) 0.17 −33.0 (−66.5, 0.6) 0.06 
AST (U/L) −5.3 
(25.6) 
−11.2 
(62.2) 
−24.5 (50.2) 13.0 (−7.0, 33.1) 0.20 −17.7 (−40.3, 5.0) 0.14 
GGT (U/L) 18.7 
(111.6) 
123.8 
(263.9) 
−16.6 
(180.0) 
152.0 (3.8, 300.2) 0.044 
−24.9 (−156.5, 
106.6) 
0.70 
Total bilirubin 
(µmol/L) 
0.7 (3.2) 10.0 (45.8) −0.5 (3.8) 
9.0 (−10.2, 28.1) 0.47 −0.8 (−17.8, 16.2) 0.93 
Fibrosis biomarkers 
Pro-C3 (ng/mL)  3.5 (8.8) −6.3 (14.3) −9.0 (14.9) −9.5 (−17.1, −2.0) 0.014 −13.3 (−21.0, −5.6) 0.001 
ELF score 0.1 (0.5) −0.3 (0.5) −0.3 (0.7) −0.4 (−0.7, 0) 0.049 −0.4 (−0.8, −0.1) 0.023 
Hyaluronic acid 
(µg/L) 
−12.3 
(71.9) 
−37.6 
(129.4) 
−0.6 (35.2) −14.9 (−45.7, 16.0) 0.34 −11.7 (−43.2, 19.8) 0.46 
PIIINP (µg/L) 1.4 (5.3) −3.6 (3.7) −3.9 (3.0) −5.0 (−7.7, −2.3) <0.001 −5.5 (−8.3, −2.8) <0.001 
TIMP-1 (µg/L) 2.6 (59.5) −31.1 
(43.2) 
−35.1 (70.2) −35.2 (−73.7, 3.3) 0.07 −37.7 (−76.5, 1.0) 0.06 
Lipids 
Triglycerides 
(mmol/L) 
0.1 (0.3) 0 (0.6) 0 (0.4) 0 (−0.3, 0.2) 0.79 −0.2 (−0.5, 0.1) 0.21 
Cholesterol  
(mmol/L) 
0.2 (0.7) 0.1 (1.0) 0.2 (1.1) 0 (−0.7, 0.6) 0.92 0.1 (−0.6, 0.8) 0.89 
HDL cholesterol 
(mmol/L) 
−0.1 (0.2) 0 (0.5) 0 (0.5) 0.1 (−0.2, 0.4) 0.59 0.1 (−0.2, 0.3) 0.62 
LDL cholesterol 
(mmol/L) 
0.1 (0.5) 0.1 (0.8) 0.3 (0.7) −0.1 (−0.6, 0.4) 0.73 0.2 (−0.4, 0.7) 0.73 
Change from baseline at week 12 in ALP (primary outcome) was compared vs placebo using the Wilcoxon Rank Sum test. Change from baseline at week 12 in 
other measures was compared vs placebo using an ANCOVA model with treatment group, visit, treatment group by visit interaction, UDCA use, treatment 
group by UDCA use interaction as classification variables and baseline value as covariate. 
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CI, confidence interval; ELF, enhanced 
liver fibrosis; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LS, least squares mean; PIIINP, N-terminal 
pro-peptide of type III collagen; Pro-C3, neoepitope-specific N-terminal pro-peptide of type III collagen; SD, standard deviation; SE, standard error; TIMP-1, 
tissue inhibitor of metalloproteinase 1 
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Table 3. Change in Bile Acids from Baseline to Week 12 
 Change from Baseline to Week 12, mean (SD) LS Mean Difference (95% CI) (NGM282 vs Placebo) 
 
Placebo 
(n=20) 
NGM282 
1mg (n=21) 
NGM282 3mg 
(n=21) 
NGM282 1mg 
P 
NGM282 3mg 
P 
Conjugated Primary Bile Acids 
GCA (µmol/L) −1.1 (6.8) −10.6 (25.4) −2.9 (10.1) −1.3 (−4.8, 2.1) 0.44 −2.8 (−6.2, 0.6) 0.10 
TCA (µmol/L) 0.8 (5.4) −4.5 (15.3) −1.2 (5.0) −0.6 (−4.4, 3.1) 0.73 −3.0 (−6.6, 0.7) 0.11 
GCDCA (µmol/L) −3.9 (14.6) −7.6 (14.7) −2.7 (11.3) −3.0 (−7.6, 1.6) 0.20 −2.6 (−7.3, 2.0) 0.26 
TCDCA (µmol/L) −1.1 (10.7) −1.1 (5.1) −0.8 (3.7) −0.9 (−3.9, 2.1) 0.55 −2.4(−5.5, 0.7) 0.12 
Conjugated Secondary Bile Acids 
GDCA (µmol/L) 0.3 (1.9) −2.2 (3.8) −1.4 (1.9) −1.0 (−1.6, −0.3) 0.003 −1.2 (−1.8, −0.6) <0.001 
TDCA (µmol/L) 0.4 (1.4) −0.4 (1.0) −0.4 (0.8) −0.3 (−0.9, 0.2) 0.19 −0.6 (−1.1, 0) 0.033 
GLCA (µmol/L) 0 (0.3) −0.1 (0.2) −0.1 (0.3) −0.1 (−0.2, 0) 0.036 −0.1 (−0.2, 0) 0.027 
TLCA (µmol/L) 0.03 (0.09) −0.02 (0.04) −0.04 (0.09) −0.05 (−0.10, 
−0.01) 
0.024 −0.06 (−0.11, 
−0.02) 
0.007 
Unconjugated Primary Bile Acids 
CA (µmol/L) 0.2 (0.6) −0.1 (0.5) 0 (0.2) −0.2 (−0.4, 0.1) 0.27 −0.1 (−0.4, 0.2) 0.51 
CDCA (µmol/L) 0.1 (0.8) −0.1 (0.3) 0.1 (0.2) −0.2 (−0.5, 0.1) 0.17 0 (−0.3, 0.2) 0.78 
Unconjugated Secondary Bile Acids 
DCA (µmol/L) 0 (0.2) −0.1 (0.1) −0.2 (0.4) −0.1 (−0.2, −0.1) <0.001 −0.2 (−0.2, −0.1) <0.001 
LCA (µmol/L) 0 (0.03) −0.02 (0.05) −0.05 (0.15) −0.01 (−0.03, 
0.01) 
0.31 −0.02 (−0.04, 
0.01) 
0.16 
UDCA and derivatives 
GUDCA (µmol/L) −10.0 (39.2) −9.7 (26.8) 1.0 
(20.1) 
−2.2 (−18.1, 13.7) 0.78 3.2 (−12.9, 19.3) 0.69 
TUDCA (µmol/L) −2.0 (7.5) −0.7 (2.8) 0 (1.5) −0.2 (−2.1, 1.7) 0.86 −0.6 (−2.5, 1.4) 0.57 
UDCA (µmol/L) −3.0 (10.1) −0.5 (4.1) 1.2 (7.1) 1.1 (−2.6, 4.9) 0.55 2.5 (−1.2, 6.3) 0.18 
Total endogenous bile acids 
TEBA (µmol/L) −4.1 (27.4) −19.7 (37.0) −9.6 (31.8) −8.6 (−20.8, 3.6) 0.16 −12.7 (−25.0, 
−0.5) 
0.042 
Change from baseline at week 12 in bile acids was compared vs placebo using an ANCOVA model with treatment group, visit, treatment group by 
visit interaction, UDCA use, treatment group by UDCA use interaction as classification variables and baseline value as covariate. 
CA, cholic acid; CDCA, chenocholic acid; DCA, deoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenocholic acid; GDCA, glycodeoxycholic acid; 
GLCA, glycolithocholic acid; GUDCA, glycoursodeoxycholic acid; LCA, lithocholic acid; TCA, taurocholic acid; TCDCA, taurochenocholic acid; TDCA, 
taurodeoxycholic acid; TEBA, total endogenous bile acids; TLCA, taurolithocholic acid; TUDCA, tauroursodeoxycholic acid; UDCA, ursodeoxycholic 
acid  
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Table 4. Summary of Adverse Events 
 Placebo 
(n=20) 
 
NGM282 1 mg 
(n=21) 
 
NGM282 3 mg 
(n=21) 
 
Adverse event, n (%) 
Overall 18 (90) 17 (81) 20 (95) 
Grade 1 8 (40)  9 (43) 6 (29) 
Grade 2  9 (45)  7 (33) 12 (57) 
Grade 3 1 ( 5)  1 ( 5) 2 ( 10) 
Grade 4  0 0 0 
At least one drug-related 
adverse event, n (%) 
13 (65)  13 (62) 16 (76) 
At least one serious adverse 
event 
0  1# (5) 2^ ( 10) 
At least one adverse event 
leading to study drug 
discontinuation 
0  1# ( 5) 1* ( 5) 
Most Common (>10%) Adverse Events, n (%) 
 Injection site reactions 1 (5) 2 (10) 11 (52) 
 Diarrhea 1 (5) 8 (38) 7 (33) 
 Abdominal pain 2 (10) 3 (14) 1 (5) 
 Nausea 4 (20) 2 (10) 3 (14) 
 Headache 3 (15) 0 (0) 4 (19) 
Nasopharygitis 4 (20) 1 (5) 2 (10) 
 Frequent bowel movements 0 (0) 3 (14) 3 (14) 
 Increased appetite 0 (0) 4 (19) 1 (5) 
 Fatigue 3 (15) 1 (5) 3 (14) 
Investigators rated the severity of each adverse event (mild [grade 1], moderate [grade 2], or severe [grade 3]). The events were classified 
according to Medical Dictionary for Regulatory Activities (MedDRA) preferred terms. No grade 4 or grade 5 (death) events were reported 
during the trial period (including follow up period after end of treatment). No cases of pancreatitis were reported. 
#SAE PSC progression (not related) 
^SAEs were bowel obstruction (possibly related) and intervertebral discitis (not related) 
*Diarrhea 
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FIGURE LEGENDS  
 
Figure 1. Trial Profile. AE, adverse event; ALP,  alkaline phosphatase; ALT, alanine aminotransferase; 
AST, aspartate aminotransferase; EOT, end of treatment. 
 
Figure 2. Key Outcome Measures. (A) Serum levels of ALP at baseline and week 12. (B) Serum levels of 
C4 at baseline and week 12. (C) Serum levels of total endogenous bile acids at baseline and week 12. 
(D) Change in ALT from baseline over time. (E) Change in AST from baseline over time.  
All data are mean ± s.e.m. Statistical tests were ANCOVA (panels A-C) or mixed-effect model repeated 
measures (panels D-E) analyses. ***P<0.001, **P<0.01, *P<0.05. ALP, alkaline phosphatase; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; C4, 7alpha-hydroxy-4-cholesten-3-one; 
EOT, end of treatment at week 12. 
 
Figure 3. Changes in Biomarkers of Liver Fibrosis. (A) Change in ELF from baseline to week 12. Left 
panel: all patients; middle panel: patients with baseline ELF ≤9.8; right panel: patient with baseline ELF 
>9.8. (B) Serum concentrations of Pro-C3 over time. (C) Percent change in Pro-C3 from baseline over 
time.  All data are mean ± s.e.m. Statistical tests were ANCOVA (panel A) or mixed-effect model 
repeated measures (panels B-C) analyses. ***P<0.001, **P<0.01, *P<0.05. ELF, Enhanced Liver Fibrosis 
score; EOT, end of treatment at week 12; FU, follow-up at week 16; Pro-C3, neoepitope-specific N-
terminal propeptide of type III collagen. 
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Highlights for manuscript JHEPAT-D-18-01614R1 by Hirschfield et al. 
NGM282 for Primary Sclerosing Cholangitis: a Multicentre, Randomized, Double-Blind, Placebo-Controlled Phase 
2 Trial   
 
 NGM282 is a first-in-class, engineered analogue of the endocrine hormone FGF19 
 Administration of NGM282 did not significantly affect alkaline phosphatase levels in patients with 
primary sclerosing cholangitis 
 However, NGM282 significantly inhibited bile acid synthesis and improved serum markers of 
fibrogenesis and liver injury  
 These findings challenge the dogma about what the appropriate endpoints should be for trials in PSC 
 
  
 
95 patients 
screened 
62 randomized 
20 assigned to 
receive placebo 
     20 received 
placebo 
 
21 assigned to receive 
NGM282 3 mg 
     21 received 
NGM282 3 mg 
 
21 assigned to receive 
NGM282 1 mg 
     21 received NGM282 
1 mg 
 
1 discontinued 
treatment 
1 patient choice 
1 discontinued 
treatment   
     1 due to AE 
2 discontinued 
treatment  
1 due to AE 
1 patient choice 
20 included in intention-to-
treat analysis 
21 included in intention-to-
treat analysis 21 included in intention-to-treat analysis 
33 excluded: 
10 did not meet ALP criteria 
4 did not meet ALT, AST or bilirubin criteria 
1 withdrew consent   
18 did not meet criteria (other) 
Hirschfield et al., Figure 1
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